Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy
Language English Country Austria Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antiparkinson Agents pharmacology therapeutic use MeSH
- Adult MeSH
- Voice Quality drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Parkinson Disease complications diagnosis drug therapy MeSH
- Speech Disorders drug therapy etiology MeSH
- Disease Progression MeSH
- Prospective Studies MeSH
- Speech drug effects MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antiparkinson Agents MeSH
Despite the initial reports showing beneficial effects of dopaminergic treatment on speech in Parkinson's disease (PD), more recent studies based upon valid measurements have not approved any improvement of speech performance under pharmacotherapy. The aim of this study was to analyze the effect of treatment initiation on the progression of speech impairment in PD, using novel evaluation criteria. Nineteen de novo patients with PD were tested and retested within 2 years after the introduction of antiparkinsonian therapy. As controls, 19 age-matched individuals were recorded. Speech examination included sustained phonation, fast syllable repetition, reading text, and monolog. Quantitative acoustic analyses of the key aspects of speech based on Gaussian kernel distribution, statistical decision-making theory, and healthy speech observation were used to assess the improvement or deterioration of speech. A trend for speech performances to improve was demonstrated after treatment mainly in quality of voice, intensity variability, pitch variability, and articulation. The treatment-related improvement differed in various aspects of speech for individual PD patients. Improvements in vowel articulation and pitch variability correlated with treatment-related changes in bradykinesia and rigidity, whereas voice quality and loudness variability improved independently. Using a novel approach of acoustic analysis and advanced statistics, improvements in speech performance can be demonstrated in PD patients after the introduction of antiparkinsonian therapy. Moreover, changes in speech articulation and pitch variability appear to be related with dopaminergic responsiveness of bradykinesia and rigidity. Therefore, speech may be a valuable marker of disease progression and treatment efficacy in PD.
See more in PubMed
Clin Neurol Neurosurg. 2007 Jul;109(6):495-500 PubMed
Eur Neurol. 1977;15(1):34-9 PubMed
Mov Disord. 2008 Apr 30;23(6):824-9 PubMed
J Commun Disord. 2002 May-Jun;35(3):217-39 PubMed
J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):319-24 PubMed
Laryngoscope. 1999 Aug;109(8):1287-94 PubMed
Int J Lang Commun Disord. 2000 Jul-Sep;35(3):407-18 PubMed
Nature. 1971 Jun 4;231(5301):315-6 PubMed
NeuroRehabilitation. 2002;17(3):237-46 PubMed
Arch Neurol. 2001 Oct;58(10):1611-5 PubMed
J Speech Hear Disord. 1963 Aug;28:221-9 PubMed
Acta Psychol (Amst). 1998 Nov;100(1-2):71-84 PubMed
J Speech Lang Hear Res. 1997 Jun;40(3):615-26 PubMed
J Acoust Soc Am. 2008 Sep;124(3):1638-52 PubMed
J Acoust Soc Am. 2011 Jan;129(1):350-67 PubMed
IEEE Trans Biomed Eng. 2009 Apr;56(4):1015 PubMed
J Speech Lang Hear Res. 2010 Feb;53(1):114-25 PubMed
Mov Disord. 2008 Mar 15;23(4):574-80 PubMed
Parkinsonism Relat Disord. 1997 Apr;3(2):111-6 PubMed
J Voice. 1997 Sep;11(3):314-20 PubMed
J Voice. 2011 Jul;25(4):467-72 PubMed
J Neurol Neurosurg Psychiatry. 1971 Dec;34(6):679-81 PubMed
Lancet Neurol. 2004 Sep;3(9):547-56 PubMed
Neurology. 2000 Jan 25;54(2):458-62 PubMed
J Gerontol. 1990 Mar;45(2):P35-45 PubMed
Mov Disord. 2009 Apr 15;24(5):716-22 PubMed
J Commun Disord. 1975 Sep;8(3):271-9 PubMed
Folia Phoniatr Logop. 2005 Jan-Feb;57(1):28-37 PubMed
J R Soc Interface. 2011 Jun 6;8(59):842-55 PubMed
J Commun Disord. 2000 Jan-Feb;33(1):59-88 PubMed
Folia Phoniatr (Basel). 1993;45(4):157-64 PubMed
Biomed Eng Online. 2007 Jun 26;6:23 PubMed
Neurology. 1973 Aug;23(8):865-70 PubMed
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed
J Fluency Disord. 2003 Spring;28(1):55-70 PubMed
J Speech Lang Hear Res. 2007 Aug;50(4):899-912 PubMed
Neurology. 1982 Jul;32(7):749-54 PubMed
Arch Neurol. 2005 Mar;62(3):378-82 PubMed
N Engl J Med. 2006 Aug 31;355(9):896-908 PubMed
J Speech Hear Disord. 1978 Feb;43(1):47-57 PubMed
Ann Otol Rhinol Laryngol. 1995 Mar;104(3):197-202 PubMed
Mov Disord. 2011 Aug 15;26(10):1951-2 PubMed
Mov Disord. 2011 Jan;26(1):59-64 PubMed
J Neural Transm (Vienna). 2010 Feb;117(2):197-205 PubMed
Behav Neurol. 1998;11(3):131-137 PubMed
Phys Ther. 2008 Jun;88(6):733-46 PubMed
Acta Neurol Belg. 2006 Mar;106(1):19-22 PubMed
J Commun Disord. 1986 Oct;19(5):347-66 PubMed
J Am Geriatr Soc. 1970 Feb;18(2):142-51 PubMed
Ann Otol Rhinol Laryngol. 2002 Jan;111(1):15-20 PubMed
J Speech Hear Res. 1969 Jun;12(2):246-69 PubMed
Med Sci Monit. 2005 Mar;11(3):CR109-16 PubMed
Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease
Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease
Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinson's disease
A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse
